Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00480-2
Affiliations:
11
Authors:
11
Go to article
Institutions Authors Share
Amgen, United States of America (USA)
4.000000
 0.36
Essen University Hospital, Germany
1.000000
 0.09
Providence Swedish, United States of America (USA)
1.000000
 0.09
University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany
1.000000
 0.09
Rabin Medical Center (RMC), TAU, Israel
1.000000
 0.09
Samsung Medical Center (SMC), South Korea
1.000000
 0.09
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA)
1.000000
 0.09
Bern University Hospital, Switzerland
1.000000
 0.09
Interested in Oncology and Carcinogenesis?